Newsbenzinga
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
· Published
Article summary
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in private financing for Phase 2 clinical trials.
An excerpt from the original article.
Comments —
Loading comments…